



Update on the Janssen® (JNJ) Ad26.COV2.S vaccine


Professor Linda-Gail Bekker



REPUBLIC OF SOUTH AFRICA



Sisonke provided the Janssen® (JNJ) Ad26.COV2.S vaccine to health workers ahead of the third wave



Sisonke Completed 17th May 2021



122

sites touched in total
including rural extensions
and mobiles

477 234


vaccinated health workers



Criteria Considered for Analysis

- Adjudication of infections: Mild/Mod/Severe
- Used 3 data sets: 2 from medical insurers and one provincial persal data
- Used 2-3 different analytical methods
- For today we report on 2 data sets

When breakthrough infections happen they are mild



Primary outcome: Effect on hospitalisation during the third wave

Sample population	Vaccinated				Unvaccinated				Vaccine Effectiveness (95% CI)
	N	P-Y	Event number	Rate 100 P-Y	N	P-Y	Event number	Rate 100 P-Y	
Population 1	64 640	10 468	59	0.56	64 559	10 416	168	1.61	65% (61%-70%)
Population 2	108 148	24 460	186	0.76	216 152	48 909	998	2.04	63% (61 – 65%)
Population 3	12 094				22305				69% (48-82%) 80% (32-94%)

Death VE : 81% - 96%